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Background: The Middle East Respiratory Syndrome coronavirus (MERS-CoV) is an emerging respiratory pathogen
with a high mortality rate and no specific treatments available to date. The purpose of this study was to determine
the feasibility of conducting a randomized controlled trial (RCT) of convalescent plasma therapy for MERS-CoV-infected
patients by using MERS-CoV-specific convalescent plasma obtained from previously recovered patients.
Methods: A survey was adapted from validated questionnaire originally aimed to measure network capacities and
capabilities within the International Severe Acute Respiratory and emerging Infection Consortium (ISARIC). The
questionnaire was modified for this study to include 26 items that were divided into three main domains of interest:
(1) the ability to care for critically ill MERS-CoV patients; (2) laboratory capacity to diagnose MERS-CoV and blood bank
ability to prepare convalescent plasma; and (3), research capacity to conduct randomized controlled trials. The
questionnaire was emailed to physicians.
Results: Of 582 physicians who were invited to the survey, 327 responded (56.2 %). The professional focus of the
majority of respondents was critical care (106/249 (43 %)), pediatrics (59/249, (24 %)) or internal medicine (52/249
(21 %)) but none was blood banking. Nearly all respondents (251/263 (95 %)) reported to have access to ICU facilities
within their institutions. Most respondents (219/270 (81 %)) reported that intensivists were the most physician group
responsible for treatment decisions about critically ill SARI patients. While 125/165 respondents (76 %) reported that
they conduct research in ICUs, and 80/161 (49.7 %) had been involved in the conduct of RCTs, including using a
placebo comparison (60/161 (37 %)), only 49/226 (21 %) of respondents regularly participated in research networks.
Conclusions: Our survey indicated that in the Kingdom of Saudi Arabia (KSA), ICUs are the most likely clinical
locations for conducting a clinical trial of convalescent plasma therapy for MERS-CoV, and that most ICUs have
experience with such research designs.
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A novel coronavirus was first diagnosed in Saudi Arabia
in June 2012 in a man who presented with pneumonia
and acute renal failure [1]. This newly discovered virus
leading to severe pneumonia and acute respiratory dis-
tress syndrome (ARDS) was later named Middle East
respiratory syndrome coronavirus (MERS-CoV). As
of July 3, 2016, there have been 1769 laboratory-
confirmed cases of MERS-CoV infection, 85 % of which
occurred in the Kingdom of Saudi Arabia [2]. The case
fatality rate is 35 % and reaches 70 % in critically ill pa-
tients [3] with no specific therapy available to date.
Convalescent plasma that contains MERS-CoV-specific
immunoglobulin and is obtained from previously recovered
patients has been suggested as a potential therapy for pa-
tients with MERS-CoV infection. Convalescent plasma has
been used to treat several other viral infections, including
the Severe Acute Respiratory Syndrome (SARS) SARS
coronavirus (SARS-CoV), Spanish influenza A (H1N1),
avian influenza A (H5N1), and 2009 pandemic influenza
A (H1N1 pdm09) [4–10]. A recent meta-analysis of obser-
vational studies of passive immunotherapy in SARS and
severe influenza suggest reductions in mortality with
timely use of convalescent blood products, particularly
those with neutralizing antibodies [11]. Public Health
England and the International Severe Acute Respiratory
& Emerging Infection Consortium (ISARIC) have pub-
lished a decision-support tool for clinicians managing
cases of MERS-CoV infection [12], which relies heavily
upon expert opinion and clinical experience of treating
patients with severe respiratory disease caused by other
viruses including SARS and 2009 pandemic influenza A
(H1N1pdm09). The document suggests that current
evidence is strongest for testing convalescent plasma
(CP) or other therapeutics which contain neutralizing
antibodies (such as hyperimmune immunoglobulin) for
treatment of serious MERS-CoV illness.
Given the scattered distribution of cases in Saudi
Arabia, it is unclear whether the clinical and research
infrastructure would be sufficient to support the con-
duction of a randomized controlled trial (RCT) of con-
valescent plasma therapy. Such a study will require
laboratory ability to diagnose MERS-CoV infection and
identify antibody titers among previously infected but
recovered patients, research infrastructure and ability
to lead or participate in an RCT, and the presence of
personal and community equipoise among healthcare
workers and patients to enroll in such a trial. There-
fore, as part of a collaborative effort among colleagues
from the Gulf States and Eastern Mediterranean and
with the support of the World Health Organization and
International Severe Acute Respiratory and Emerging
Infection Consortium, we undertook a survey to assess




The study targeted health care specialists in internal
medicine, critical care, respiratory disease, infectious
disease, hematology, and pediatrics, along with clinical
microbiologists, hospital epidemiologists and blood
bankers. The survey consisted of voluntary anonymous
responses to a web-based questionnaire and did not in-
clude actual patient data.
Questionnaire development
A validated questionnaire, previously used by ISARIC to
evaluate and map capacity conduct of clinical trials in
response to outbreaks, was used as a basis for the devel-
opment of this survey. Omitting questions that were
deemed not relevant to this study, and modifying or
adding questions that were more appropriate to the
current objectives led to a questionnaire of 26 items, di-
vided into three main domains of interest. First, four
questions aimed to evaluate the ability and capacity of
caring for critically ill patients within the KSA health
system (e.g., “How many beds are capable of caring for
mechanically ventilated patients in the ICU where pa-
tients with severe acute respiratory infection (SARI)
would usually be treated?”). Second, the study sought to
explore laboratory capacity to diagnose MERS-CoV in-
fection and Blood Bank ability to prepare convalescent
plasma through seven questions (e.g., “Do you have a
mechanism to send specific blood donors (e.g., survivors
of MERS-CoV infection) to the blood bank to make do-
nations?” and “What methodologies are available in the
laboratories associated with your site for MERS-coV
testing?”). The third domain aimed to evaluate research
capacity needed to conduct clinical trials and whether or
not necessary infrastructure to conduct RCTs existed in
KSA, through 10 questions specifically related to re-
search (e.g., “Do you believe that patients at your hos-
pital would participate in randomized studies in which
patients are randomly assigned to one of two or more
treatments?”). The questionnaire was populated using
Survey Monkey, was emailed through the snowball
methodology, to physicians who are possibly involved
in the care of MERS-CoV patients. Snowball sampling
is a chain referral sampling where the initial participants
are asked to assist in recruiting more subjects by passing
on the questionnaire. We initiated contact with 250 partic-
ipants from 48 hospitals in Saudi Arabia; those in turn
invited others, with a total subjects approached being
approximately 582. There were three reminders, 2 weeks
apart by email to non-respondents, and the data was col-
lected between March and May 2014. A complete list of
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(Additional file 1). The Institutional Review Board (IRB) of
Ministry of National Guard Health Affairs (RC14/003/R–
29 April 2015) approved this study. The first question of
the survey was a question about whether the participant
consents to the survey.
Statistical analysis
Descriptive statistics (frequencies and percentages) were
used to quantify the categorical study variables.
Results
ICU capacity
Of 582 physicians who were invited to the survey, 327
responded (56.2 %) (Table 1). The professional focus of
the majority of respondents was critical care (106/249
(43 %)), pediatrics (59/249 (24 %)) or internal medicine
(52/249 (21 %)) but none was blood banking. Nearly all
respondents (251/263, 95 %) reported to have access to
ICU facilities within their institutions and 44 % of theseTable 1 Respondent and ICU characteristics
Questions Responders to the
The professional focus of the respondentsa 249
The presence of ICU in the hospitalb 263
Number of ICU beds capable of caring for mechanically
patients ventilated with SARI
285
Specific therapies available in the ICU 259
The most responsible physician group for treatment
decisions about critically ill patients
270
aMore than one answer is possible
bICU is defined as a geographic location in the hospital where patients with severe acuICUs had more than 20 beds. Most respondents (219/
270 (81 %)) reported that intensivists were the most
physician group responsible for treatment decisions
about critically ill SARI patients. Available reported ther-
apies in the ICUs included extra-corporal membrane
oxygenation (ECMO) (48 %), hemodialysis (91 %) and
plasmapheresis (82 %).
Laboratory capacity
Majority of the respondents (235/250 (94 %)) indicated
that blood products used in their hospitals were ob-
tained in the same hospital, only 15/250 (6 %) reported
that blood products are obtained from a blood bank at
another institution. When asked about the feasibility of
having MERS-CoV infection survivors to donate blood/
plasma, 130/237 (55 %) of the respondents reported this
would be feasible (Table 2). A majority (240/248
(97 %)) of the respondents reported to have access to
the necessary facilities and capabilities for screening
for blood-borne viruses in donated blood within theirQuestion Answer options Responders
Critical care 106 (42.5)
Pediatrics 59 (23.6)
Internal medicine 52 (20.9)
Respiratory 37 (14.8)
Infectious diseases 34 (13.6)










Extra-corporeal membrane oxygenation (ECMO) 125 (48.2)
Hemodialysis 235 (90.7)
Plasmapheresis and/or plasma exchange 212 (81.8)
Care to pediatric patients 222 (85.7)
Intensivists 219 (81.1)
Pulmonologists 17 (6.2)




te respiratory infection (SARI) can be treated with invasive mechanical ventilation
Table 2 Laboratory capacity questions
Questions Responders to the Question Answer options Responders
The source of blood products? 250 Blood bank in your facility 235 (94.0)
Blood bank from another facility 15 (6.0)
Feasibility of obtaining blood donation from specific groups
(e.g., survivors of MERS-CoV)
237 Yes 130 (54.9)
The capability to screen for blood-borne viruses in donated
blood (e.g., HIV, hepatitis, etc.)?
248 Yes 240 (96.8)
Ability to send suspected MERS-CoV samples to a reference
laboratory for diagnosis?
226 Yes 173 (76.5)












Methodologies for MERS-CoV testinga 205 Real-time PCR Yes 135
No 10
Do not know 57
Sequencing Yes 22
No 21
Do not know 110
Serology Yes 51
No 21
Do not know 88
Other (please specify) 8
Available diagnostic work-up for severe acute
respiratory infectiona
218 Blood cultures Yes 205
No 4
Do not know 6
Urine bacterial antigen testing Yes 153
No 28
Do not know 30
Viral antigen testing Yes 146
No 36
Do not know 28
PCR for bacterial and viral testing Yes 170
aMore than one answer is possible
Arabi et al. BMC Anesthesiology  (2016) 16:36 Page 4 of 7institutions. In regards to laboratory testing for MERS-
CoV, 173/226 (77 %) reported that samples for MERS-
CoV testing were sent to reference laboratories for diagno-
sis, with 147/164 (90 %) reported that the results wereobtained within seven days. Other microbiologic tests for
pneumonia work-up were reported to be available as fol-
lows: 95 % blood cultures, 73 % for urine bacterial antigen
testing, 70 % for viral antigen testing, and 79 % for PCR
Table 3 Research capacity questions
Questions Responders Answer options Responders
Regular participation of the respondent in a specific
research network(s)?
226 Yes 49 (21.7)
The predominant focus of the networka 114 Clinical infectious diseases 46 (40.3)
Microbiology or virology 24 (21.0)
Critical care 71 (62.2)
Public or global health 34 (29.8)
Other (please specify) 11 (9.6)
Participation in research initiativesa 148 Local clinical research initiatives 130 (87.8)
National clinical research initiatives 67 (45.3)
International clinical research initiatives 55 (37.2)
Age categories of patients are recruited into studies
at the respondent sitea
165 Adult 139 (84.2)
Pediatrics 56 (33.9)
Settings in the hospital that conduct clinical researcha 165 Emergency department 66 (40.0)
Hospital wards 104 (63.0)
ICUs 125 (75.8)
Outpatient/community care settings 75 (45.5)
Other 5 (3.0)
Research types in the respondent hospitala 161 Retrospective observational studiesb 147 (91.3)
Prospective observational studies 115 (71.4)
Biological sampling studies (blood and other fluids) 79 (49.1)
Randomized clinical trials of interventions 80 (49.7)
Clinical trials using a placebo control comparison group 60 (37.3)
Do you believe that patients at your hospital would
participate in randomized studies?
181 Definitely not 8 (4.4)
Probably not 31 (17.1)
Maybe 70 (38.7)
Probably yes 49 (27.1)
Definitely 23 (12.7)
The presence of registry data (i.e., an electronic or
hard-copy database)
179 Yes 146 (81.6)
aMore than one answer is possible
bRetrospective observational studies include case reports, chart review case series, case-control studies, cohort studies
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the most commonly available diagnostic test was real-time
PCR (67 %) and the least available methodology was gene
sequencing (14 %).
Research capacity
Most respondents reported involvement in local clinical
research initiatives (88 %) while only 21 % of respon-
dents claimed to be part of specific research networks,
predominantly focused upon clinical infectious diseases
and critical care and the focus of investigation was
mostly (84 %) upon adults. Most research (76 %) is per-
ceived to take place in ICUs (76 %) and hospital wards
(63 %) (Table 3). Of the physicians surveyed, 91 %
worked at hospitals that have participated inretrospective observational studies, while 71 % reported
being involved in prospective studies or trials. Only half
of the respondents (49 %) perceived their institutions
had been involved with biological sampling studies (of
blood and other fluids) or randomized clinical trials of
interventions (50 %), while only 37 % knew of their in-
stitutions having been involved in clinical trials using a
placebo control comparison group.
A majority 146/179 (82 %) of respondents said that they
had access to registry data for patients receiving care at
their sites, and more than 50 % of respondents reported
that their institutions had a research administration infra-
structure in place to aid with data-sharing agreements
(52 %), research contract (49 %), ethics reviews (74 %), and
administrative support for research projects (60 %). The
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sion to approval to enroll patients) was approximately 1 to
3 months.
Although 22 % of respondents said that the patients at
their hospital were definitely not or probably not likely
to participate in randomized studies and 39 % said that
they were ‘maybe’ prepared to parttake in such studies,
40 % of respondents said they believed their patients
would probably or definitely agree to participate.
Discussion
Our survey identifies that many healthcare facilities in
KSA have the necessary capacity to participate RCTs that
enroll severely ill patients with MERS-CoV infection. The
survey highlights a few important points in support of this
conclusion. First, most respondents believed that the
needed infrastructure was in place – such as data regis-
tries, laboratory capacity, ethics review processes, and
monitoring units for RCTs. Second, respondents seemed
to be aware of the required capacity for research in
MERS-CoV. Third, although not the most common trial
design in Saudi Arabia, most respondents were aware of
RCTs and what they entail, and a majority of them
believed that their patients would consider participating in
RCTs. However, many barriers to conducting RCTs re-
main. First, there is low community awareness of research
in general, which is needed for any RCT to take place. Sec-
ond there may be lengthy processes required to obtain
regulatory and ethics approval to initiate clinical trials.
This survey suggests that the necessary clinical and
laboratory facilities exist to conduct such RCTs. The
presence of ICUs with sufficient numbers of beds is a
necessary component of conducting RCTs on potential
therapies for critically ill patients with MERS-CoV. Essen-
tial laboratory infrastructure for such studies are also
available including blood banking, microbiologic diagnos-
tic testing for pneumonia in general and MERS-CoV in
particular. However, as none of the respondents was a
blood bank specialist, it is not possible to explore this in
greater detail on the basis of this survey alone. A majority
of the respondents (54.9 %) reported that sending individ-
uals who had recovered from MERS-CoV to donate blood
is feasible, which is a positive and necessary step for
obtaining convalescent plasma.
There are a number of limitations associated with this
study. Because of the snowball methodology, the number
of subjects who were approached is only approximate.
Response rate was modest, and response rates to individual
questions varied. Due to the anonymity of replies to this
survey it has not been possible to follow up on incomplete
responses. There were no responses from blood banks. As
with other surveys, it is possible that individuals motivated
to conduct research or work in institutions that conduct
research were more likely to respond to the survey; creatinga bias towards more favorable answers for research in-
frastructure and culture. The study did not include a
face-to-face interview, which would have resulted in
higher targeted responses. Finally, surveys represent stated
responses as opposed to measurement of actual practice.
Conclusions
Our survey results indicate that the research infrastruc-
ture at many acute care facilities in Saudi Arabia is likely
generally sufficient to conduct a RCT to investigate the
efficacy of convalescent plasma treatment for severely ill
patients with MERS-CoV. Next steps in such a research
program will need to include an observational study of
actual clinical and diagnostic practice in the care of pa-
tients with MERS-CoV in KSA. This would help to in-
form design of a pilot clinical trial with a goal to
demonstrate feasibility and safety of convalescent plasma
evaluation, and would need to occur before a true evalu-
ation of efficacy could take place.
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